Lifecore Biomedical to Participate at CPHI Global Conference

Q: Who from Lifecore Biomedical will attend the CPHI Global Conference 2026?

Attendees from Lifecore Biomedical include chief commercial officer Mark DaFonseca and business development directors Mary Evelyn Hudson, Edward Purell, and Dan Dennehy. They will host meetings with prospective customers at booth 8J60.

Lifecore plans customer meetings on injectable CDMO services at the CPHI Global Conference in Milan in October 2026.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Lifecore Biomedical (LFCR) will participate in the CPHI Global Conference taking place October 6-8, 2026, in Milan, Italy.

Company leaders, including chief commercial officer Mark DaFonseca and business development directors Mary Evelyn Hudson, Edward Purell, and Dan Dennehy, will host meetings with prospective customers to discuss process development and manufacturing services for injectable programs at booth 8J60. Interested parties are invited to schedule meetings via the provided CDMO email contact.

Argus Sep 4 session 7 alerts

+1.15% close to close 3.7x rel. volume Open Argus

Details

News Market Reaction – LFCR

$174.12M Mkt Cap at Peak Alert

On Sep 4, the first trading day after this news, LFCR closed 1.15% above the previous close. Our momentum scanner recorded 7 alerts for this stock that day. Relative volume reached 3.7x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 4 session.

Key Figures

Conference dates: October 6-8, 2026 Company expertise: more than 40 years

Conference dates: October 6-8, 2026; CPHI Global Conference in Milan, Italy
Company expertise: more than 40 years; Injectable-grade hyaluronic acid manufacturing expertise

Historical Context

5 past events · Latest: Sep 02

5 events

Sep 02
Commercial site transfer

24h Move

+8.0%

Added a late-stage commercial program to Lifecore's CDMO pipeline.
Aug 05
Q2 earnings report

24h Move

+2.1%

Revenue declined and net loss widened, despite reaffirmed full-year guidance.
Jul 29
Q2 reporting notice

24h Move

+0.9%

Announced the August 5 release date for second-quarter financial results.
Jul 28
Customer agreements

24h Move

+1.1%

Signed three agreements expanding early- and late-stage CDMO programs.
Jul 15
Inducement grant

24h Move

+1.9%

Granted restricted stock units covering 3,500 common shares to a new employee.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cdmo, fill and finish

2 terms

cdmo financial

"a fully integrated injectables contract development and manufacturing organization"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

fill and finish technical

"capabilities in the development, fill and finish of sterile injectable"

The final stage of producing biological medicines where bulk drug substance is transferred into final dosage forms—filling vials, syringes, or cartridges—and then sealed, labeled and packaged for distribution. It matters to investors because this step determines how quickly a treatment can reach patients, creates manufacturing bottlenecks or capacity value, and often involves specialized facilities and regulatory controls; think of it as the bottling and labeling line in a beverage plant that readies product for sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/03/2026 - 04:05 PM EDT

CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the CPHI Global Conference. The conference will take place October 6-8, 2026, in Milan, Italy.

Details regarding Lifecore’s participation are as follows:

CPHI Global Conference
Details: Lifecore leaders, including Mark DaFonseca, chief commercial officer, and business development directors Mary Evelyn Hudson, Edward Purell, and Dan Dennehy, will host meetings with prospective customers to discuss process development and manufacturing services for injectable programs.
Booth number: 8J60
Conference Dates: October 6-8, 2026
Location: Fiera Milano, Italy

If you are interested in meeting with Lifecore during this event, please reach out to us at: cdmo@lifecore.com.

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com

Jennifer Arcure (Media)
917-603-0681
jarcure@vidasp.com

Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
ryan.lake@lifecore.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will Lifecore Biomedical (LFCR) participate in the CPHI Global Conference?

Lifecore Biomedical will participate in the CPHI Global Conference from October 6-8, 2026, at Fiera Milano in Milan, Italy. The company plans on-site meetings with prospective customers during the three-day event.

What is Lifecore Biomedical (LFCR) presenting or discussing at the CPHI Global Conference?

Lifecore Biomedical leaders will host meetings with prospective customers to discuss process development and manufacturing services for injectable programs. The focus is on the company’s CDMO capabilities in sterile injectable pharmaceuticals, including complex formulations.

Where is Lifecore Biomedical’s booth located at the CPHI Global Conference 2026?

Lifecore Biomedical’s booth at the CPHI Global Conference 2026 is booth 8J60. Company leaders will be available there to meet with prospective customers and discuss injectable contract development and manufacturing services.

How can potential customers schedule a meeting with Lifecore Biomedical (LFCR) at CPHI Global 2026?

Potential customers interested in meeting Lifecore Biomedical during CPHI Global 2026 are asked to contact the company by email at cdmo@lifecore.com. Meetings will focus on process development and manufacturing services for injectable pharmaceutical programs.

Who from Lifecore Biomedical will attend the CPHI Global Conference 2026?

Attendees from Lifecore Biomedical include chief commercial officer Mark DaFonseca and business development directors Mary Evelyn Hudson, Edward Purell, and Dan Dennehy. They will host meetings with prospective customers at booth 8J60.

Lifecore Biomedical to Participate at CPHI Global Conference